EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a cross-protective common cold coronavirus vaccine

Tanushree Dangi iD, Shiyi Li, Pablo Penaloza-MacMaster iD

Journal of Virology · 2025

DOI: 10.1128/jvi.01526-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Tanushree Dangi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Common Cold, Spike Glycoprotein, Coronavirus, Viral Vaccines, Cross Protection. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Common cold coronaviruses, such as OC43 and HKU1, typically cause mild respiratory infections in healthy people. However, they can lead to severe illness in high-risk groups, including immunocompromised individuals and older adults. Currently, there is no clinically approved vaccine to prevent infection by common cold coronaviruses. Here, we developed an mRNA vaccine expressing a stabilized spike protein derived from OC43 coronavirus and tested its efficacy in different challenge models in C57BL/6 mice. This novel OC43 vaccine elicited OC43-specific immune responses, as well as cross-reactive immune response against other embecoviruses, including HKU1 and mouse hepatitis virus (MHV-A59). Interestingly, this OC43 vaccine protected mice not only against a lethal OC43 infection but also against a distant embecovirus, MHV-A59. These findings provide insights for the development of common cold coronavirus vaccines, demonstrating their potential to protect against various coronaviruses. IMPORTANCE Human coronaviruses like OC43 cause disease in vulnerable populations, yet no approved vaccines exist. We developed an mRNA vaccine targeting the OC43 spike protein that protects mice not only against homologous OC43 challenges but also against the distantly related embecovirus MHV-A59. These findings demonstrate the feasibility of a single vaccine conferring broad protection across multiple coronaviruses within the same subgenus, advancing strategies for pan-coronavirus vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Common ColdSpike Glycoprotein, CoronavirusViral VaccinesCross ProtectionCoronavirus OC43, HumanCoronavirus InfectionsAnimalsMiceMice, Inbred C57BLHumansFemaleAntibodies, ViralMurine hepatitis virusCross ReactionsVaccines, SyntheticVaccine Development

Stichwörter der Autor:innen

HCoV-OC43coronaviruscross-protective immunityvaccines

Substanzen

Spike Glycoprotein, CoronavirusViral VaccinesAntibodies, ViralVaccines, Synthetic

Autor:innen und Institutionen

  • Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

ORCID-Profile: Tanushree Dangi, Pablo Penaloza-MacMaster

Zitieren

APA

Dangi, T., Li, S., & Penaloza-MacMaster, P. (2025). Development of a cross-protective common cold coronavirus vaccine. Journal of Virology. https://doi.org/10.1128/jvi.01526-25

Vancouver

Dangi T, Li S, Penaloza-MacMaster P. Development of a cross-protective common cold coronavirus vaccine. Journal of Virology. 2025. doi:10.1128/jvi.01526-25

BibTeX
@article{Dangi2025,
  author = {Dangi, Tanushree and Li, Shiyi and Penaloza-MacMaster, Pablo},
  title = {Development of a cross-protective common cold coronavirus vaccine},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.01526-25}
}
Kostenlos starten →